GSK Seeks To Forgo Trial In First Zofran MDL Bellwether

Law360, Boston (January 15, 2020, 6:50 PM EST) -- GlaxoSmithKline argued in court Wednesday to prevail on simply a paper record in the first trial in a multidistrict case over whether the company's anti-nausea medication Zofran caused birth defects, claiming a California mother cannot show she wouldn't have taken Zofran anyway, even with a birth defect warning.

The hearing marked a drilling down on the specifics of a single case, the first bellwether currently set to begin in May. In that trial, the family of Maya Rodriguez will make the case that when her mother, Carla, took Zofran in 2004 during pregnancy, it led to Maya being born with a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS